市場調査レポート
商品コード
1692343

スターガルト病治療薬市場- 世界の産業規模、シェア、動向、機会、予測、薬物タイプ別、流通チャネル別、地域別、競合別、2020-2030年

Stargardt Disease Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Distribution Channel, By Region & Competition, 2020-2030F
表紙：スターガルト病治療薬市場- 世界の産業規模、シェア、動向、機会、予測、薬物タイプ別、流通チャネル別、地域別、競合別、2020-2030年

出版日
ページ情報
英文 185 Pages
納期
2～3営業日
カスタマイズ可能
スターガルト病治療薬市場- 世界の産業規模、シェア、動向、機会、予測、薬物タイプ別、流通チャネル別、地域別、競合別、2020-2030年
出版日: 2025年03月24日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2～3営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

世界のスターガルト病治療薬市場は、2024年に2億275万米ドルと評価され、2030年までのCAGRは7.50%で、予測期間中に目覚ましい成長を予測しています。

遺伝性の眼疾患であるスターガルト病では、中心視力を明瞭にするために重要な役割を果たす黄斑が悪影響を受ける。この疾患は通常、小児期または青年期に発症し、徐々に視力が低下します。現在、スターガルト病に対して承認された治療法はないが、病態を管理し、進行を阻止する可能性のある治療法の開発には大きな進展が見られます。例えば、WHOは2023年に、世界中で22億人以上が視力障害を抱えており、少なくとも10億人が予防可能または未対処であると報告しています。失明と視力喪失の主な原因は屈折異常と白内障であり、眼科医療と予防措置の改善が急務であることが浮き彫りになっています。

市場概要
予測期間 2026-2030
市場規模：2024年 2億275万米ドル
市場規模：2030年 3億1,041万米ドル
CAGR：2025年～2030年 7.50%
急成長セグメント LBS-008
最大市場 北米

市場促進要因

普及率と認知度の向上

主な市場課題

疾患メカニズムに対する理解の浅さ

主要市場動向

遺伝子治療のブレークスルー

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のスターガルト病治療薬市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 薬剤タイプ別（LBS-008、エミクススタト）
    • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
    • 地域別
    • 企業別（2024）
  • 製品市場マップ
    • 薬の種類別
    • 流通チャネル別
    • 地域別

第6章 北米のスターガルト病治療薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州のスターガルト病治療薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン

第8章 アジア太平洋地域のスターガルト病治療薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国

第9章 南米のスターガルト病治療薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカのスターガルト病治療薬市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の動向
  • 合併と買収
  • 製品上市

第13章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第14章 競合情勢

  • Kubota Pharmaceutical Holdings Co Ltd
  • IVERIC bio Inc
  • Sanofi SA
  • Alkeus Pharmaceuticals Inc
  • Astellas Pharma Inc
  • Cha Biotech Co Ltd/Old
  • reVision Therapeutics, Inc.
  • Biogen Inc
  • F Hoffmann-La Roche AG
  • Ocugen Inc

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 18728

Global Stargardt Disease Therapeutics Market was valued at USD 202.75 million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.50% through 2030. In Stargardt disease, an inherited eye condition, the macula, which plays a crucial role in clear central vision, is adversely affected. This condition typically manifests in childhood or adolescence and gradually leads to a decline in visual acuity. While there are currently no approved treatments for Stargardt disease, significant progress has been made in the development of therapeutic approaches aimed at managing the condition and potentially arresting its progression. For instance, in 2023, WHO reported that over 2.2 billion people worldwide have vision impairment, with at least 1 billion cases preventable or unaddressed. The primary causes of blindness and vision loss globally are refractive errors and cataracts, highlighting the urgent need for improved eye care and preventive measures.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 202.75 Million
Market Size 2030USD 310.41 Million
CAGR 2025-20307.50%
Fastest Growing SegmentLBS-008
Largest MarketNorth America

Key Market Drivers

Increased Prevalence and Awareness

The prevalence of Stargardt Disease has been on the rise, with an increasing number of individuals being diagnosed with this condition worldwide. While it remains a rare disease, the broader global population and improved diagnostic capabilities have led to more cases being identified. This heightened prevalence underscores the urgency of finding effective treatments and therapies for those affected. For instance, in 2025, Ascidian Therapeutics has received FDA authorization to begin a Phase 1/2 clinical trial for ACDN-01, its RNA editing therapy for Stargardt disease, a genetic eye disorder caused by ABCA4 mutations. Unlike traditional gene therapies, ACDN-01 rewrites RNA exons to restore healthy protein production, potentially benefiting many affected individuals.

Stargardt Disease primarily affects children and young adults, but the ageing population has also contributed to its increasing prevalence. As the global population continues to age, the demand for treatments for age-related eye conditions, including Stargardt Disease, is expected to grow significantly. This demographic shift amplifies the market potential for Stargardt Disease therapeutics.

Key Market Challenges

Limited Understanding of the Disease Mechanism

Despite significant progress, our understanding of the exact mechanisms underlying Stargardt Disease remains incomplete. This knowledge gap can impede the development of targeted therapies and necessitates ongoing research to uncover the complexities of the condition.

Key Market Trends

Gene Therapy Breakthroughs

Gene therapy is emerging as a promising avenue in the quest to treat Stargardt Disease. Researchers are conducting clinical trials to test the safety and efficacy of gene therapies that aim to replace or correct the faulty genes responsible for the condition. As trials progress, breakthroughs that bring gene therapy closer to becoming a viable treatment option are likely to come up.

Key Market Players

  • Kubota Pharmaceutical Holdings Co Ltd
  • IVERIC bio Inc
  • Sanofi SA
  • Alkeus Pharmaceuticals Inc
  • Astellas Pharma Inc
  • Cha Biotech Co Ltd/Old
  • reVision Therapeutics, Inc.
  • Biogen Inc
  • F Hoffmann-La Roche AG
  • Ocugen Inc

Report Scope:

In this report, the Global Stargardt Disease Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Stargardt Disease Therapeutics Market, By Drug Type:

  • LBS-008
  • Emixustat

Stargardt Disease Therapeutics Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Stargardt Disease Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Stargardt Disease Therapeutics Market.

Available Customizations:

Global Stargardt Disease Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Stargardt Disease Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (LBS-008, Emixustat)
    • 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Product Market Map
    • 5.3.1. By Drug Type
    • 5.3.2. By Distribution Channel
    • 5.3.3. By Region

6. North America Stargardt Disease Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type (LBS-008, Emixustat)
    • 6.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Stargardt Disease Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Stargardt Disease Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Stargardt Disease Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Distribution Channel

7. Europe Stargardt Disease Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type (LBS-008, Emixustat)
    • 7.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Stargardt Disease Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. United Kingdom Stargardt Disease Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. France Stargardt Disease Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Stargardt Disease Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Stargardt Disease Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Distribution Channel

8. Asia-Pacific Stargardt Disease Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type (LBS-008, Emixustat)
    • 8.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Stargardt Disease Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. Japan Stargardt Disease Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. India Stargardt Disease Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. Australia Stargardt Disease Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. South Korea Stargardt Disease Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Distribution Channel

9. South America Stargardt Disease Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type (LBS-008, Emixustat)
    • 9.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Stargardt Disease Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. Argentina Stargardt Disease Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. Colombia Stargardt Disease Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Stargardt Disease Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type (LBS-008, Emixustat)
    • 10.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Stargardt Disease Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Saudi Arabia Stargardt Disease Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. UAE Stargardt Disease Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Distribution Channel
    • 10.3.4. Kuwait Stargardt Disease Therapeutics Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Drug Type
        • 10.3.4.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Kubota Pharmaceutical Holdings Co Ltd
    • 14.1.1. Business Overview
    • 14.1.2. Product Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. IVERIC bio Inc
  • 14.3. Sanofi SA
  • 14.4. Alkeus Pharmaceuticals Inc
  • 14.5. Astellas Pharma Inc
  • 14.6. Cha Biotech Co Ltd/Old
  • 14.7. reVision Therapeutics, Inc.
  • 14.8. Biogen Inc
  • 14.9. F Hoffmann-La Roche AG
  • 14.10.Ocugen Inc

15. Strategic Recommendations

16. About Us & Disclaimer